Osanetant (SR-142,801) was a neurokinin 3 receptor antagonist developed by Sanofi-Synthélabo, which was being researched for the treatment of schizophrenia, but was discontinued. It was the first non-peptide NK3 antagonist developed in the mid-1990s, Other potential applications for osanetant is in the treatment of drug addiction, as it has been found to block the effects of cocaine in animal models.
^Kamali, F (July 2001). "Osanetant Sanofi-Synthélabo". Current opinion in investigational drugs (London, England : 2000). 2 (7): 950–6. PMID11757797.
^Emonds-Alt, X; Bichon, D; Ducoux, JP; Heaulme, M; Miloux, B; Poncelet, M; Proietto, V; Van Broeck, D; et al. (1995). "SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor". Life Sciences. 56 (1): PL27–32. PMID7830490. doi:10.1016/0024-3205(94)00413-M.